Cargando…
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra,...
Ejemplares similares
-
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021) -
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial
por: Akinosoglou, Karolina, et al.
Publicado: (2022) -
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
por: Samaras, Charilaos, et al.
Publicado: (2023) -
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019) -
Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial
por: Tsiakos, Konstantinos, et al.
Publicado: (2021)